Cannabinoid modulation of opioid analgesia and subjective drug effects in healthy humans

[1]  C. Haylock,et al.  Conditions , 2019, Intermediate Ancient Greek Language.

[2]  M. Wall,et al.  The neuropsychopharmacology of cannabis: A review of human imaging studies , 2019, Pharmacology & therapeutics.

[3]  F. Blyth,et al.  Effect of cannabis use in people with chronic non-cancer pain prescribed opioids: findings from a 4-year prospective cohort study. , 2018, The Lancet. Public health.

[4]  C. France,et al.  Reinforcing effects of opioid/cannabinoid mixtures in rhesus monkeys responding under a food/drug choice procedure , 2018, Psychopharmacology.

[5]  Theodore L. Caputi,et al.  Medical Marijuana Users are More Likely to Use Prescription Drugs Medically and Nonmedically , 2018, Journal of addiction medicine.

[6]  S. Skaper,et al.  A Pharmacological Rationale to Reduce the Incidence of Opioid Induced Tolerance and Hyperalgesia: A Review , 2018, Pain and Therapy.

[7]  D. Piomelli,et al.  Endocannabinoid System and Migraine Pain: An Update , 2018, Front. Neurosci..

[8]  G. Bedi,et al.  Impact of co-administration of oxycodone and smoked cannabis on analgesia and abuse liability , 2018, Neuropsychopharmacology.

[9]  W. Bradford,et al.  Medical Marijuana Laws May Be Associated With A Decline In The Number Of Prescriptions For Medicaid Enrollees. , 2017, Health affairs.

[10]  Richard E. Harris,et al.  Endogenous opioidergic dysregulation of pain in fibromyalgia: a PET and fMRI study , 2016, Pain.

[11]  G. Bedi,et al.  Oral Cannabidiol does not Alter the Subjective, Reinforcing or Cardiovascular Effects of Smoked Cannabis , 2016, Neuropsychopharmacology.

[12]  D. Clauw,et al.  Medical Cannabis Use Is Associated With Decreased Opiate Medication Use in a Retrospective Cross-Sectional Survey of Patients With Chronic Pain. , 2016, The journal of pain : official journal of the American Pain Society.

[13]  Robert Kay,et al.  Substituting cannabis for prescription drugs, alcohol and other substances among medical cannabis patients: The impact of contextual factors. , 2016, Drug and alcohol review.

[14]  R. Chou,et al.  CDC Guideline for Prescribing Opioids for Chronic Pain--United States, 2016. , 2016, JAMA.

[15]  C. France,et al.  Effects of daily delta-9-tetrahydrocannabinol treatment on heroin self-administration in rhesus monkeys , 2016, Behavioural pharmacology.

[16]  R. Chou,et al.  CDC Guideline for Prescribing Opioids for Chronic Pain - United States, 2016. , 2016, MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports.

[17]  Janet Woodcock,et al.  A Proactive Response to Prescription Opioid Abuse. , 2016, The New England journal of medicine.

[18]  D. Tauben,et al.  CDC guideline for prescribing opioids for chronic pain , 2016 .

[19]  S. Walsh,et al.  Pharmacodynamic effects of oral oxymorphone: abuse liability, analgesic profile and direct physiologic effects in humans , 2016, Addiction biology.

[20]  S. Walsh,et al.  Quinine as a potential tracer for medication adherence: A pharmacokinetic and pharmacodynamic assessment of quinine alone and in combination with oxycodone in humans , 2015, Journal of clinical pharmacology.

[21]  J. Lötsch,et al.  THC may reproducibly induce electrical hyperalgesia in healthy volunteers , 2015, European journal of pain.

[22]  C. Cunningham,et al.  Medical cannabis laws and opioid analgesic overdose mortality in the United States, 1999-2010. , 2014, JAMA internal medicine.

[23]  Anoumid Vaziri,et al.  Cannabinoid receptors in the basolateral amygdala are involved in the potentiation of morphine rewarding properties in the acquisition, but not expression of conditioned place preference in rats , 2014, Brain Research.

[24]  R. Charnigo,et al.  Pharmacokinetic and Pharmacodynamic Profile of Supratherapeutic Oral Doses of Δ9‐THC in Cannabis Users , 2013, Journal of clinical pharmacology.

[25]  C. France,et al.  Interactions between μ-Opioid Receptor Agonists and Cannabinoid Receptor Agonists in Rhesus Monkeys: Antinociception, Drug Discrimination, and Drug Self-Administration , 2013, The Journal of Pharmacology and Experimental Therapeutics.

[26]  W. Koek,et al.  Interactions between &Dgr;9-tetrahydrocannabinol and heroin: self-administration in rhesus monkeys , 2012, Behavioural pharmacology.

[27]  Asbjørn Mohr Drewes,et al.  Human Experimental Pain Models for Assessing the Therapeutic Efficacy of Analgesic Drugs , 2012, Pharmacological Reviews.

[28]  N. Benowitz,et al.  Cannabinoid–Opioid Interaction in Chronic Pain , 2011, Clinical pharmacology and therapeutics.

[29]  W. Fratta,et al.  Differential effect of opioid and cannabinoid receptor blockade on heroin‐seeking reinstatement and cannabinoid substitution in heroin‐abstinent rats , 2011, British journal of pharmacology.

[30]  G. Wasner,et al.  Topical high-concentration (40%) menthol-somatosensory profile of a human surrogate pain model. , 2011, The journal of pain : official journal of the American Pain Society.

[31]  D. Walsh,et al.  Opioid and Adjuvant Analgesics: Compared and Contrasted , 2011, The American journal of hospice & palliative care.

[32]  J. Long,et al.  Fatty acid amide hydrolase and monoacylglycerol lipase inhibitors produce anti-allodynic effects in mice through distinct cannabinoid receptor mechanisms. , 2010, The journal of pain : official journal of the American Pain Society.

[33]  W. Ling,et al.  Gabapentin improves cold-pressor pain responses in methadone-maintained patients. , 2010, Drug and alcohol dependence.

[34]  J. Lötsch,et al.  Analgesic efficacy of tramadol, pregabalin and ibuprofen in menthol-evoked cold hyperalgesia , 2009, PAIN®.

[35]  Asbjørn Mohr Drewes,et al.  Assessing analgesic actions of opioids by experimental pain models in healthy volunteers - an updated review. , 2009, British journal of clinical pharmacology.

[36]  S. Welch.  Interaction of the cannabinoid and opioid systems in the modulation of nociception , 2009, International review of psychiatry.

[37]  S. Walsh,et al.  The relative abuse liability of oral oxycodone, hydrocodone and hydromorphone assessed in prescription opioid abusers. , 2008, Drug and alcohol dependence.

[38]  R. Frey,et al.  Lack of Analgesia by Oral Standardized Cannabis Extract on Acute Inflammatory Pain and Hyperalgesia in Volunteers , 2008, Anesthesiology.

[39]  R. Jamison,et al.  Efficacy of dronabinol as an adjuvant treatment for chronic pain patients on opioid therapy. , 2008, The journal of pain : official journal of the American Pain Society.

[40]  Serge Marchand,et al.  Analgesic and antihyperalgesic effects of nabilone on experimental heat pain , 2008, Current medical research and opinion.

[41]  I. Abramson,et al.  Dose-dependent Effects of Smoked Cannabis on Capsaicin-induced Pain and Hyperalgesia in Healthy Volunteers , 2007, Anesthesiology.

[42]  P. Beaulieu.  Effects of nabilone, a synthetic cannabinoid, on postoperative pain , 2006, Canadian journal of anaesthesia = Journal canadien d'anesthesie.

[43]  John D. Roberts,et al.  Synergistic affective analgesic interaction between delta-9-tetrahydrocannabinol and morphine. , 2006, European journal of pharmacology.

[44]  L. Panlilio,et al.  Cannabinoid Agonists but not Inhibitors of Endogenous Cannabinoid Transport or Metabolism Enhance the Reinforcing Efficacy of Heroin in Rats , 2005, Neuropsychopharmacology.

[45]  D. Cichewicz.  Synergistic interactions between cannabinoid and opioid analgesics. , 2004, Life sciences.

[46]  L. Arendt-Nielsen,et al.  The analgesic effect of oral delta-9-tetrahydrocannabinol (THC), morphine, and a THC-morphine combination in healthy subjects under experimental pain conditions , 2003, Pain.

[47]  Erin A. Mccarthy,et al.  Antinociceptive Synergy between Δ9-Tetrahydrocannabinol and Opioids after Oral Administration , 2003, Journal of Pharmacology and Experimental Therapeutics.

[48]  M. Greenwald,et al.  Antinociceptive, subjective and behavioral effects of smoked marijuana in humans. , 2000, Drug and alcohol dependence.

[49]  Michael L. Eads,et al.  Synergistic interactions of endogenous opioids and cannabinoid systems , 1999, Brain Research.

[50]  S. Welch,et al.  Enhancement mu opioid antinociception by oral delta9-tetrahydrocannabinol: dose-response analysis and receptor identification. , 1999, The Journal of pharmacology and experimental therapeutics.

[51]  Daniel R. McLeod,et al.  An automated version of the digit symbol substitution test (DSST) , 1982 .

[52]  D. W. Goodwin,et al.  Marihuana and pain , 1974, Pain.

[53]  H. Isbell,et al.  Cross tolerance between mescaline and LSD-25 with a comparison of the mescaline and LSD reactions , 1962, Psychopharmacologia.

[54]  W. Martin,et al.  Methods for evaluating addiction liability. (A) "Attitude" of opiate addicts toward opiate-like drugs. (B) a short-term "direct" addiction test. , 1961, The Journal of pharmacology and experimental therapeutics.

[55]  M. Olfson,et al.  Cannabis Use and Risk of Prescription Opioid Use Disorder in the United States. , 2018, The American journal of psychiatry.

[56]  W. Koek,et al.  Interactions between delta 9-tetrahydrocannabinol and heroin : self-administration in rhesus monkeys , 2015 .

[57]  J. Stinson,et al.  Pharmacological management of chronic neuropathic pain - consensus statement and guidelines from the Canadian Pain Society. , 2007, Pain research & management.